Randomized Phase II Study of CABAZITAXEL versus METHOTREXATE in patients with recurrent or metastatic squamous cell carcinoma of the head and neck previously treated with platinum-based therapy

Trial Profile

Randomized Phase II Study of CABAZITAXEL versus METHOTREXATE in patients with recurrent or metastatic squamous cell carcinoma of the head and neck previously treated with platinum-based therapy

Completed
Phase of Trial: Phase II

Latest Information Update: 19 Jun 2017

At a glance

  • Drugs Cabazitaxel (Primary) ; Methotrexate
  • Indications Head and neck cancer
  • Focus Therapeutic Use
  • Acronyms RACATREX
  • Most Recent Events

    • 02 Jun 2015 Primary endpoint (Progression-free survival rate) has not been met as per results presented at the 51st Annual Meeting of the American Society of Clinical Oncology. .
    • 02 Jun 2015 Results presented at the 51st Annual Meeting of the American Society of Clinical Oncology.
    • 29 Sep 2012 New source identified and integrated (European Clinical Trials Database: EudraCT2011-001938-42).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top